This technology is a method to target and eliminate the viral reservoir of latent HIV-1 using latency reversal agents facilitated by targeted delivery with bispecific monoclonal antibodies.
This technology describes human monoclonal antibodies derived from the B cells of a case of zoonotic avian influenza virus H7N9 to treat or prevent H7N9 infections.
This technology is a pharmacological intervention targeting localized inflammatory responses in trauma and hemorrhagic shock to prevent multiple organ failure.
